New MGA Analysis of the Adalimumab Biosimilars Market in the United States

Feb 21, 2023 | Analysis, Press Releases

New MGA Analysis of the Adalimumab Biosimilars Market in the United States Below is the press release from Biosimilars Council regarding the new report from MGA examining biosimilar competition for Humira (adalimumab) in the US market. Washington, D.C. (February 21,...

New MGA Analysis of Biosimilar Coverage in Commercial Medical Benefit

Dec 8, 2022 | Analysis

New MGA Analysis of Biosimilar Coverage in Commercial Medical Benefit A new MGA white paper from CEO Alex Brill and Principal Christy Robinson shows a positive outlook for biosimilar coverage in the commercial medical benefit. While patients and physicians play a role...

Updated MGA Report Presents Biosimilar Market Opportunities in Ophthalmology

Jul 14, 2022 | Analysis

Updated MGA Report Presents Biosimilar Market Opportunities in Ophthalmology MGA releases an updated report, “Biosimilar Market Opportunities in Ophthalmology.”  Authored by founder and CEO Alex Brill, the report examines the economics of biologic drugs for...

New MGA Report Presents Biosimilar Market Opportunities in Ophthalmology

May 26, 2022 | Analysis

New MGA Report Presents Biosimilar Market Opportunities in Ophthalmology MGA releases a new report, “Biosimilar Market Opportunities in Ophthalmology.” Authored by founder and CEO Alex Brill, the report examines current trends and economics in the ophthalmology...

Observable Flaws in CMS’s Dialysis Star-Rating System and a Proposed Alternative

May 1, 2015 | Analysis

Observable Flaws in CMS’s Dialysis Star-Rating System and a Proposed Alternative Alex Brill | Bloomberg BNA In January 2015, CMS launched a star-rating system for U.S. dialysis facilities. This article analyzes nearly 6,000 U.S. dialysis facilities and explores...